Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study

Currently, there are limited treatment options for patients who developed resistance to osimertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor. Resistance to EGFR inhibitors is frequently associated with enhanced vascular endothelial growth factor (VEGF) levels. This multi...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Xue Yang, Yang Xia, Liyan Xu, Li Liang, Minglei Zhuo, Meina Wu, Tongtong An, Ziping Wang, Yuyan Wang, Jianjie Li, Jia Zhong, Hanxiao Chen, Bo Jia, Jingjing Wang, Jun Zhao
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Frontiers Media S.A. 2021-05-01
Seri Bilgileri:	Frontiers in Molecular Biosciences
Konular:	osimertinib apatinib EGFR NSCLC resistance
Online Erişim:	https://www.frontiersin.org/articles/10.3389/fmolb.2021.639892/full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!